These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32489980)

  • 1. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
    Piao J; Lim HJ; Lee M
    Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis.
    Wang YM; Cai W; Xue QM; Zhang JY; Zhou L; Xiong SY; Deng H
    Front Immunol; 2023; 14():1234894. PubMed ID: 37654479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Cui Q; Li W; Wang D; Wang S; Yu J
    World J Surg Oncol; 2023 Oct; 21(1):318. PubMed ID: 37821941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients.
    Liu X; Shan C; Song Y; Du J
    Front Oncol; 2019; 9():1111. PubMed ID: 31709181
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
    Wang Q; Liu F; Liu L
    Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
    Wang L
    J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.
    Yang J; Dong M; Shui Y; Zhang Y; Zhang Z; Mi Y; Zuo X; Jiang L; Liu K; Liu Z; Gu X; Shi Y
    Cancer Cell Int; 2020; 20():96. PubMed ID: 32256205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
    Zeng YF; Wei XY; Guo QH; Chen SY; Deng S; Liu ZZ; Gong ZC; Zeng WJ
    Front Immunol; 2023; 14():1168244. PubMed ID: 37122727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
    Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y
    Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
    Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J
    Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
    Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
    Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
    Yang L; Xue R; Pan C
    Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.